BR9810616A - Inibidores de farnesil transferase em combinação com inibidores de hmg coa redutase para o tratamento do cancer - Google Patents

Inibidores de farnesil transferase em combinação com inibidores de hmg coa redutase para o tratamento do cancer

Info

Publication number
BR9810616A
BR9810616A BR9810616-3A BR9810616A BR9810616A BR 9810616 A BR9810616 A BR 9810616A BR 9810616 A BR9810616 A BR 9810616A BR 9810616 A BR9810616 A BR 9810616A
Authority
BR
Brazil
Prior art keywords
inhibitors
combination
coa reductase
hmg coa
cancer treatment
Prior art date
Application number
BR9810616-3A
Other languages
English (en)
Inventor
Shama Mohammed Kajiji
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR9810616A publication Critical patent/BR9810616A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: <B>''INIBIDORES DE FARNESIL TRANSFERASE EM COMBINAçãO COM INIBIDORES DE HMG CoA REDUTASE PARA O TRATAMENTO DO CANCER"<D>. A presente invenção refere-se a um método para o tratamento do câncer num mamífero, incluindo um ser humano, por administração ao mamífero de um inibidor de FTase em combinação com um inibidor de HMG CoA redutase.
BR9810616-3A 1997-06-16 1998-06-05 Inibidores de farnesil transferase em combinação com inibidores de hmg coa redutase para o tratamento do cancer BR9810616A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4963897P 1997-06-16 1997-06-16
PCT/IB1998/000881 WO1998057633A1 (en) 1997-06-16 1998-06-05 FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG CoA REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER

Publications (1)

Publication Number Publication Date
BR9810616A true BR9810616A (pt) 2000-09-12

Family

ID=21960890

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9810616-3A BR9810616A (pt) 1997-06-16 1998-06-05 Inibidores de farnesil transferase em combinação com inibidores de hmg coa redutase para o tratamento do cancer

Country Status (37)

Country Link
EP (1) EP0986387B1 (pt)
JP (1) JP3713051B2 (pt)
KR (1) KR100392573B1 (pt)
CN (1) CN1259868A (pt)
AP (1) AP9801261A0 (pt)
AR (1) AR013090A1 (pt)
AT (1) ATE235905T1 (pt)
BG (1) BG103946A (pt)
BR (1) BR9810616A (pt)
CA (1) CA2294399C (pt)
CO (1) CO4950607A1 (pt)
DE (1) DE69812933T2 (pt)
DK (1) DK0986387T3 (pt)
DZ (1) DZ2518A1 (pt)
EA (1) EA199901043A1 (pt)
ES (1) ES2196559T3 (pt)
GT (1) GT199800081A (pt)
HN (1) HN1998000091A (pt)
HR (1) HRP980328B1 (pt)
HU (1) HUP0004624A3 (pt)
ID (1) ID23014A (pt)
IL (1) IL132765A0 (pt)
IS (1) IS5259A (pt)
MA (1) MA24569A1 (pt)
NO (1) NO996206L (pt)
NZ (1) NZ500662A (pt)
OA (1) OA11231A (pt)
PA (1) PA8453601A1 (pt)
PE (1) PE82899A1 (pt)
PL (1) PL337651A1 (pt)
PT (1) PT986387E (pt)
SK (1) SK169699A3 (pt)
TN (1) TNSN98088A1 (pt)
TR (1) TR199903074T2 (pt)
UA (1) UA57081C2 (pt)
WO (1) WO1998057633A1 (pt)
ZA (1) ZA985182B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200000660A (et) * 1998-05-12 2002-04-15 Warner-Lambert Company Valk farnesüültransferaasi ja HMG CoA reduktaasi inhibiitorite kombinatsioonid ja nende kasutamine vähi raviks
AU6256499A (en) * 1998-09-24 2000-04-10 Merck & Co., Inc. A method of treating cancer
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
AU4988100A (en) * 1999-05-07 2000-11-21 Brigham And Women's Hospital Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
CA2632091C (en) 2000-12-19 2011-03-22 Pfizer Products Inc. Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production
JP4092203B2 (ja) 2000-12-21 2008-05-28 ニトロメッド，インク． 新規のシクロオキシゲナーゼ２選択的阻害剤としての置換アリール化合物、組成物、および使用方法
US20020151563A1 (en) * 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
JP2005200419A (ja) * 2004-01-16 2005-07-28 National Health Research Inst 癌治療法
US8168667B2 (en) 2006-05-31 2012-05-01 Galapagos Nv Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
GB2463514C (en) 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0856315B1 (en) * 1995-08-09 2005-08-24 Banyu Pharmaceutical Co., Ltd. Protein-farnesyltransferase inhibitors in combination with hmgcoa-reductase-inhibitors for the treatment of aids

Also Published As

Publication number Publication date
KR20010013839A (ko) 2001-02-26
PL337651A1 (en) 2000-08-28
DE69812933D1 (de) 2003-05-08
AR013090A1 (es) 2000-12-13
HRP980328A2 (en) 1999-04-30
IL132765A0 (en) 2001-03-19
PE82899A1 (es) 1999-08-26
AU724676B2 (en) 2000-09-28
HUP0004624A2 (hu) 2001-10-28
ES2196559T3 (es) 2003-12-16
NO996206D0 (no) 1999-12-15
ATE235905T1 (de) 2003-04-15
BG103946A (bg) 2000-07-31
HRP980328B1 (en) 2002-06-30
AP9801261A0 (en) 1999-12-11
KR100392573B1 (ko) 2003-07-23
WO1998057633A1 (en) 1998-12-23
EP0986387A1 (en) 2000-03-22
CO4950607A1 (es) 2000-09-01
AU7445998A (en) 1999-01-04
JP3713051B2 (ja) 2005-11-02
JP2000513031A (ja) 2000-10-03
GT199800081A (es) 1999-12-07
PT986387E (pt) 2003-06-30
ZA985182B (en) 1999-12-17
ID23014A (id) 1999-12-30
IS5259A (is) 1999-11-19
MA24569A1 (fr) 1998-12-31
TNSN98088A1 (fr) 2005-03-15
EA199901043A1 (ru) 2000-06-26
CA2294399A1 (en) 1998-12-23
NZ500662A (en) 2001-10-26
TR199903074T2 (xx) 2000-05-22
DE69812933T2 (de) 2003-11-06
NO996206L (no) 2000-02-15
EP0986387B1 (en) 2003-04-02
DZ2518A1 (fr) 2003-02-01
OA11231A (en) 2003-05-26
UA57081C2 (uk) 2003-06-16
PA8453601A1 (es) 2000-05-24
CA2294399C (en) 2004-03-16
HUP0004624A3 (en) 2002-11-28
HN1998000091A (es) 1999-09-29
SK169699A3 (en) 2000-06-12
DK0986387T3 (da) 2003-07-14
CN1259868A (zh) 2000-07-12

Similar Documents

Publication Publication Date Title
AU1718400A (en) Method for treating pain
BR9809819A (pt) Compostos e métodos para a inibição da expressão de vcam-1
CA2370030A1 (en) Sodium channel blocker compositions and the use thereof
TR200200986T2 (tr) C-aril glukozid SGLT2 önleyicileri.
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
DE69124371D1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
BR9708632A (pt) Composto calcilìticos
YU20302A (sh) Upotreba retigabina u lečenju neuropatskog bola
BR9810616A (pt) Inibidores de farnesil transferase em combinação com inibidores de hmg coa redutase para o tratamento do cancer
BR9805544C1 (pt) Uso de um composto.
BR0210568A (pt) Conjugado, uso de um conjugado, composição farmacêutica, e, método para tratar câncer em um mamìfero
TR200100774T2 (tr) Bir aP2 önleyicisinin ve kombinasyonunun kullanıldığı aterosklerozis tedavi yöntemi
BR9914940A (pt) Método para aperfeiçoar a farmacocinética de tipranavir
EP0570022A3 (en) Chelants possessing ortho ligating functionality and complexes thereof
BR9916270A (pt) Combinação de cerivastatina e fibratos
BR9813996A (pt) 2-arilbenzo[b]tiofenos úteis para o tratamento de sìndrome da privação de estrogênio
BR9915692A (pt) Monohidrato de bromidrato de eletriptano
DK0613687T3 (da) Anvendelse af pregnanderivat til behandling af tumorer
GB9907571D0 (en) Compounds
BR9811643A (pt) Suplementação quìmica de osso
BR0214287A (pt) limpador contendo um inibidor de urease para reduzir a produção de amÈnia proveniente da urina
BR9813634A (pt) &#34;abridores de canal de potássio&#34;
BR0009676A (pt) Método para o tratamento e/ou profilaxia de malária, usos de atovaquona e de uma combinação de atovaquona, proguanila e primaquina, combinação de atovaquona, proguanila e primaquina, kit, e, formulação farmacêutica
BR9911220A (pt) Métodos para ampliação dos nìveis de acetilcolina
BR9911217A (pt) Métodos para ampliação dos nìveis de acetilcolina

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ARTIGO 8O DA LPI